1. IP management@universities 2014 Best practices: Univ-Ind collaborations Jo Bury, managing director VIB Istanbul, October 30 th -31 st, 2014

2. Policy factors impacting innovation: The case of Flanders Jo Bury, managing director VIB

3. Flanders anno 1994 well established support for R&D good (life) science stars of worldclass

4. Flanders anno 1994 well established support for R&D good (life) science stars of worldclass Innogenetics – Plant Genetic Systems How can we do better?

5. SWOT analysis Flanders 1994 S:- strong science base (champions) W:- no structural funding - brain drain - no tech transfer O:- develop an attraction pole of excellence - build a knowledge economy T: - loose leading position

6. Benchmarks Max Planck Society MRC UK Karolinska Institutet Cold Spring Harbor Labs Salk Institute HHMI

7. Preliminary conclusions Focus on excellence PI vs Dir as DMU Combine strenghts Build critical mass Build a tech transfer pipeline Develop a biotech cluster

8. Business plan build a new institute from scratch o attract the champions ↕ reunite the champions in 1 SRC o multisite o stringent selection

9. Business plan (2) thematic focus: o GE: molecular mechanism of life high level of ambition: o top 10% WW continuous improvement: o selection / continuation based on excellence institution: o not another granting body

10. Business plan (3) long term financial commitment: o significant (30-50%) o 22 M€/year o 5 years o renewable (if excellent) stringent selection of university departments: o 9/100 independent structure (SRC): o board of directors o own facilities (TTO)

11. Reduction to practice Minister-President: o visionary (long term view) o right combination of powers o April 1994 government of Flanders: o April 1995 foundation by notarial deed: o July 1995 operations: o January 1996

12. Reduction to practice (2) Partnership with universities university campus empower univ staff with VIB staff framework agreement VIB-univ mutual added value share return on investment –Publications: 2 affiliations –IPR: joint IP (VIB in charge)

13. VIB today

14. VIB: Mission To create groundbreaking knowledge on the molecular mechanisms ruling life for the benefit of scientific progress and the benefit of society Excellence in science + Excellence in tech transfer

15. VIB state of affairs multisite institute (JV with univ) 1350 scientists – technicians (50/50) 76 research groups 8 departments management agreement (2012-2016) 43.8 M€/year 5 years key performance indicators

16. Basic Research@VIB Molecular mechanisms molecular medecine –normal growth and development –health vs disease  neurobiology  cancer  inflammation  cardiovascular molecular farming –normal growth and development –normal vs stress

17. Basic Research@VIB centre of excellence important biological questions stimulating environment –VIB grant –research infrastructure –disruptive technologies –dialective environment –institutional integration

18. Science policy Making the Difference frontline (not me too) world class (international competition) relevance + quality good record of high impact publications and patent applications performance =

19. Results 2013

20. 620 peer reviewed publications 168 breaktrough articles (68 T1%) 70 PhD’s

21. Publications in top journals (T5%)

22. Excellence in tech transfer

23. Path towards value creation Agreements Start-ups IPR

24. An integrated and pro-active team IP Management Business DevelopmentNew Ventures License & BD deals Assessment TT Projects Start-up Projects Licensing case  Start-up case

25. A proactive IP strategy VIB patent estate: 218 patent families

26. 116 partnering agreements signed

27. VIB integrated approach towards start-ups Evaluate technology & business opportunity Build IPR platform Perform FTO analysis Conceptualize and write business plan Facilitate start-up and early stage Search for management Road show to investors VIB POC Fund Seed Capital Fund

28. VIB start-ups: from knowledge to products 608 employees

29. 8 M€ 5 M€ 14.5 M€ 20 M€ 2 M€ 5 M€ + 29 M€ => IPO => Tradesale + 25 M€ + 11 M€ => Tradesale + 25M€ + 40 M€ => IPO + 7.9 M€ + 5.1 M€ + 15.5 M€ + 10.7M€ + 5.5M€ VIB start-ups: equity investment and exit

30. Total investment in VIB start-ups (€) –VC/private:255.200.000 –IPO/PIPE/SPO:272.500.000 527.700.000 ~ 50% international VIB start-ups: a magnet for foreign investments

31. Products: therapeutic pipeline 13 therapeutics under development, including 1 small compound

32. VIB as facilitator for the biotech sector

33. Bio-incubator Leuven

34. 34 UGent Technology Park: Large Cluster in Biotech the largest R&D hub in AgBio in Europe DevGenarGEN-X Bayer Crop Science (former PGS) VIB/UGent VIB Bioincubator Actogenix, ADX Neuroscience, Biomaric, BIP, Complix, Pronota, Seps Pharma, Yakult, Q-Biologicals Bioaccelerator I Bioaccelerator II Ablynx Innogenetics IIC Ugent Oxyrane, Genohm, Biogazelle, Feops, Com & Sciense, Quinvita, Bio- Actor CropDesignAnabiotec Fytolab 1900 employees

35. Ghent Agrobiotech cluster

36. Ghent Biomed campus

37. From science to value

38. Policy factors impacting innovation: The case of Flanders Jo Bury, managing director VIB

39. Science policy (2) Making the right Choices selecting on excellence bottom up approach strategic plan (15.10) exposure to SABs monitoring (w y m i w y g) evaluation reward excellence (rotation) VIB grant allocation ~ performance